HCC

January 20, 2021January 20, 2021

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

News

First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver cancer ... Read more

November 6, 2020November 6, 2020

Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer

News

The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced or inoperable hepatocellular carcinoma (HCC), the most common form ... Read more

October 7, 2020October 7, 2020

Phase 1 Trial of ET140203 T-cell Therapy Starts Enrolling Adults With Advanced Liver Cancer

News

Eureka Therapeutics has started enrolling adults with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, in a Phase 1/2 trial of its investigational ET140203 T-cell therapy. The ... Read more

September 4, 2020September 4, 2020

FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has issued a complete response letter stating that it will not approve the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) as a first-line treatment for people ... Read more

June 3, 2020June 3, 2020

FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of newly diagnosed patients with advanced hepatocellular carcinoma (HCC), the most ... Read more

July 25, 2018July 25, 2018

FDA Expedites Tecentriq-Avastin Combo for Most Common Liver Cancer

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) for the first-line treatment of patients with advanced or metastatic hepatocellular ... Read more

September 26, 2017

FDA OKs Opdivo as Liver Cancer Therapy for Patients Who Did Not Respond to Nexavar

News

Patients with the most common liver cancer subtype, hepatocellular carcinoma (HCC), who have not responded to Nexavar (sorafenib), now can be treated with Opdivo (nivolumab), following an accelerated approval granted by the ... Read more